Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054398 | 0.87 | PARP1 (0.69) | PARP1CYP1A2 | |
| SCHEMBL17627471 | 0.86 | PARP1 (0.60) | PARP1CYP1A2 | |
| SCHEMBL20565556 | 0.83 | PARP1 (0.72) | PARP1CYP1A2 | |
| SCHEMBL4047260 | 0.77 | PARP1 (0.80) | PARP1CYP1A2 | |
| SCHEMBL17627424 | 0.76 | KDM4E (0.38) | — | |
| SCHEMBL4046195 | 0.76 | PARP1 (1.00) | PARP1CYP1A2 | |
| SCHEMBL17627401 | 0.75 | PARP1 (0.71) | PARP1CYP1A2 | |
| SCHEMBL4048006 | 0.75 | PARP1 (1.00) | PARP1CYP1A2 | |
| SCHEMBL4052397 | 0.74 | PARP1 (0.94) | PARP1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5417866 | 0.73 | PARP1 (0.67) | PARP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000814-A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | Domain Therapeutics (FR) | 2016-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | GRM1, GRM2, GRIN1 | PARP1 4590/4885CYP1A2 2158/4885 |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | PARP1 4590/4885CYP1A2 2158/4885 |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | PARP1 4640/4885CYP1A2 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.